Acrovestone
Acrovestone is a natural acetophenone dimer isolated from Acronychia pedunculata. Acrovestone inhibits 5-lipoxygenase/mPGES-1 with IC50 values of 2.7 µM and 1.1 µM, respectively. Acrovestone inhibits TbPTR1, TbDHFR, and hDHFR. Acrovestone inhibits ERK1/2, increases p38, promotes Akt/FoxO3a, inhibits BIM, upregulates Bcl-2/Bcl-xL, reduces caspase-9/3 cleavage, and modulates caspase-7. Acrovestone can serve as an antitumor compound that inhibits the growth of various cancer cells. Acrovestone can be used in research on cancers such as leukemia, cervical cancer, lung cancer, and colorectal cancer, as well as neurodegenerative diseases.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 24177-16-0
- 分子式: C32H42O8
- 分子量:554.67
-
保管条件:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
Caspase アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
|
5-Lipoxygenase 2.7 μM (IC50) |
mPGES-1 1.1 μM (IC50) |
TbPTR1 36.8 μM (EC50) |
TbDHFR 2.1 μM (IC50) |
hDHFR 19.8 μM (IC50) |
ERK1 |
ERK2 |
p38 |
Akt |
FOXO3a |
Bim |
Bcl-2 |
Bcl-xL |
Caspase-9 |
Caspase-3 |
Caspase-7 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Jurkat | IC50 |
4.9 μM
|
Antiproliferative activity against human Jurkat acute T cell leukemia cells assessed as viability reduction incubated 24 hrs by MTS assay.
Antiproliferative activity against human Jurkat acute T cell leukemia cells assessed as viability reduction incubated 24 hrs by MTS assay.
|
39073310 |
| NALM-6 | IC50 |
7.8 μM
|
Antiproliferative activity against human NALM6 B cell precursor leukemia cells assessed as viability reduction incubated 24 hrs by MTS assay.
Antiproliferative activity against human NALM6 B cell precursor leukemia cells assessed as viability reduction incubated 24 hrs by MTS assay.
|
39073310 |
| K562 | IC50 |
3.8 μM
|
Antiproliferative activity against human K562 erythroid leukemia cells assessed as viability reduction incubated 24 hrs by MTS assay.
Antiproliferative activity against human K562 erythroid leukemia cells assessed as viability reduction incubated 24 hrs by MTS assay.
|
39073310 |
| HPBALL | IC50 |
2.71 μM
|
Antiproliferative activity against human HPB-ALL T cell leukemia cells assessed as viability reduction incubated 24 hrs by MTS assay.
Antiproliferative activity against human HPB-ALL T cell leukemia cells assessed as viability reduction incubated 24 hrs by MTS assay.
|
39073310 |
| HeLa | IC50 |
0.77 μM
|
Acrovestone (compound 4 assignment) antiproliferative activity against human cervical cancer HeLa cells assessed as viability reduction incubated 72 hrs by MTT assay.
Acrovestone (compound 4 assignment) antiproliferative activity against human cervical cancer HeLa cells assessed as viability reduction incubated 72 hrs by MTT assay.
|
36302543 |
| A549 | IC50 |
1.13 μM
|
Acrovestone (compound 4 assignment) antiproliferative activity against human lung carcinoma A549 cells assessed as viability reduction incubated 72 hrs by MTT assay.
Acrovestone (compound 4 assignment) antiproliferative activity against human lung carcinoma A549 cells assessed as viability reduction incubated 72 hrs by MTT assay.
|
36302543 |
| A549 | IC50 |
6.1 μM
|
Antiproliferative activity against human A549 lung carcinoma cells assessed after 72 hrs incubation by sulforhodamine B assay.
Antiproliferative activity against human A549 lung carcinoma cells assessed after 72 hrs incubation by sulforhodamine B assay.
|
31550158 |
| MDA-MB-231 | IC50 |
6.4 μM
|
Antiproliferative activity against human MDA-MB-231 triple-negative breast cancer cells assessed after 72 hrs incubation by sulforhodamine B assay.
Antiproliferative activity against human MDA-MB-231 triple-negative breast cancer cells assessed after 72 hrs incubation by sulforhodamine B assay.
|
31550158 |
| KB | IC50 |
4.9 μM
|
Antiproliferative activity against human KB cervical carcinoma cells assessed after 72 hrs incubation by sulforhodamine B assay.
Antiproliferative activity against human KB cervical carcinoma cells assessed after 72 hrs incubation by sulforhodamine B assay.
|
31550158 |
| SH-SY5Y | IC50 |
6.12 μM
|
Cytotoxicity against human neuroblastoma SH-SY5Y cells assessed as viability after 24 hrs incubation by CCK-8 assay.
Cytotoxicity against human neuroblastoma SH-SY5Y cells assessed as viability after 24 hrs incubation by CCK-8 assay.
|
40451969 |
| SH-SY5Y | EC50 |
0.58 μM
|
Neuroprotective activity against 10 mM glutamate-induced excitotoxicity in human neuroblastoma SH-SY5Y cells assessed as viability after 24 hrs pretreatment and 24 hrs glutamate exposure by CCK-8 assay.
Neuroprotective activity against 10 mM glutamate-induced excitotoxicity in human neuroblastoma SH-SY5Y cells assessed as viability after 24 hrs pretreatment and 24 hrs glutamate exposure by CCK-8 assay.
|
40451969 |
| HCT-116 | IC50 |
0.24 μM
|
Antiproliferative activity against human HCT-116 colorectal adenocarcinoma cells assessed as viability reduction by MTT assay.
Antiproliferative activity against human HCT-116 colorectal adenocarcinoma cells assessed as viability reduction by MTT assay.
|
39073310 |
| RKO | IC50 |
1.54 μM
|
Antiproliferative activity against human RKO colon cancer cells assessed as viability reduction by MTT assay.
Antiproliferative activity against human RKO colon cancer cells assessed as viability reduction by MTT assay.
|
39073310 |
| SW480 | IC50 |
5.3 μM
|
Antiproliferative activity against human SW480 colorectal adenocarcinoma cells assessed as viability reduction by MTT assay.
Antiproliferative activity against human SW480 colorectal adenocarcinoma cells assessed as viability reduction by MTT assay.
|
39073310 |
| MCF-10A | IC50 |
15.3 μM
|
Antiproliferative activity against human MCF-10A breast epithelial cells assessed as viability reduction by MTT assay.
Antiproliferative activity against human MCF-10A breast epithelial cells assessed as viability reduction by MTT assay.
|
39073310 |
| DU-145 | IC50 |
0.93 μM
|
Cytotoxicity of Acrovestone against human DU145 prostate cancer cells assessed as viability reduction after 48 hrs incubation by MTS assay.
Cytotoxicity of Acrovestone against human DU145 prostate cancer cells assessed as viability reduction after 48 hrs incubation by MTS assay.
|
22708987 |
| A2058 | IC50 |
0.38 μM
|
Cytotoxicity of Acrovestone against human A2058 melanoma cells assessed as viability reduction after 48 hrs incubation by MTS assay.
Cytotoxicity of Acrovestone against human A2058 melanoma cells assessed as viability reduction after 48 hrs incubation by MTS assay.
|
22708987 |
体外実験
Acrovestone (0.195-100 µg/mL; 72 h) exhibits anti-proliferative activity against HeLa and A549 cells with IC50 values of 0.77 µM and 1.13 µM (as compound 5) or 5.1 µM and 11.8 µM (as compound 4), respectively[4].
Acrovestone (72 h) inhibits proliferation of A549, MDA-MB-231, KB, and KB-VIN human tumor cells with IC50 values of 6.1, 6.4, 4.9, and 4.4 µM, respectively[7].
Acrovestone has potent anti-proliferative activity against HCT-116 (IC50 0.24 μM), RKO (IC50 1.54 μM), and SW480 (IC50 5.3 μM) cancer cells in the MTT assay, and weaker activity against MCF-10A (IC50 15.3 μM)[9].
Acrovestone (dose-dependent; 48 h) shows potent cytotoxicity against DU145 human prostate cancer cells with an IC50 of 0.93 μM[10].
Acrovestone (dose-dependent; 48 h) shows potent cytotoxicity against A2058 human melanoma cells with an IC50 of 0.38 μM[10].
Acrovestone (2.3 μM; 15 min) inhibits 5-LO product formation in intact human neutrophils with an IC50 of 2.3 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HeLa and A549 cell lines
-
Concentration:0.195, 0.39, 0.78, 1.56, 3.12, 6.25, 12.5, 25, 50, 100 µg/mL
-
Incubation Time:72 h
-
Result:Exhibited anti-proliferative activity against HeLa and A549 cells, with IC50 values of 0.77 µM and 1.13 µM, respectively.
-
Cell Line:human neuroblastoma SH-SY5Y cells
-
Concentration:0.1, 0.5 µM (cytotoxicity); 0.1, 0.5, 1, 5 µM (protection)
-
Incubation Time:24 h
-
Result:Enhanced cell survival by 28% at 0.5 µM.
Not cytotoxic with IC50 6.12 µM.
Neuroprotective EC50 was 0.58 µM in the SH-SY5Y model.
At 5 µM, the cell protective effect was abolished.
Glutamate induced rounded cell shape, whereas pre-exposure at 0.5 and 0.1 µM preserved normal morphology.
-
Cell Line:human neuroblastoma SH-SY5Y cells
-
Concentration:0.1, 0.5, 1, 5 µM
-
Incubation Time:24 h
-
Result:Dose-dependently reduced glutamate-induced ERK1/2 phosphorylation.
Attenuated the glutamate-induced decrease in p38 phosphorylation levels
Dose-dependently increased Akt phosphorylation.
Increased the level of glutamate-induced FoxO3a phosphorylation.
Slightly inhibited the glutamate-induced increase in Bim levels.
Glutamate reduced the expression of Bcl-2 and Bcl-xL, whereas the addition of Acrovestone at concentrations of 0.1 μM and 0.5 μM upregulated the expression of Bcl-2 and Bcl-xL, which had been reduced by glutamate.
Bax was slightly suppressed and the Bcl-2/Bax ratio was restored.
Suppressed caspase-9 and cleaved caspase-9 dose-dependently and decreased the cleaved caspase-9/caspase-9 ratio.
Caspase-3 effect was most pronounced at 0.5 and 1 µM.
Caspase-7 was slightly increased at 0.1 and 0.5 µM.
At 0.1-1 µM, reduced cleaved caspase-3 and -7 and their ratios, whereas at 5 µM, increased caspase-7 expression and abolished protection.
化学情報
-
CAS 番号 24177-16-0
-
性状 Solid
-
分子量 554.67
-
分子式 C32H42O8
-
Color Light yellow to yellow
-
SMILES
O=C(C)C1=C(O)C(C(CC(C)C)C2=C(C(C(C)=O)=C(C(C/C=C(C)\C)=C2O)OC)O)=C(O)C(C/C=C(C)\C)=C1O
-
Structure Classification
-
Initial Source
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
純度とドキュメンテーション
-
データシート (290 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Svouraki A, et al. Evaluation of Dual 5-Lipoxygenase/Microsomal Prostaglandin E2 Synthase-1 Inhibitory Effect of Natural and Synthetic Acronychia-Type Isoprenylated Acetophenones. Journal of natural products. 2017 Mar 24;80(3):699-706. [Content Brief]
[7]. Miyake K, et al. Prenylated Acetophloroglucinol Dimers from Acronychia trifoliolata: Structure Elucidation and Total Synthesis. J Nat Prod. 2019 Oct 25;82(10):2852-2858. [Content Brief]
[10]. Kouloura E, et al. Cytotoxic prenylated acetophenone dimers from Acronychia pedunculata. Journal of natural products. 2012 Jul 27;75(7):1270-6. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Acrovestone 関連分類
HY-N16691 関連分類
Powered by Bioz